摘要研究替格瑞洛对冠心病患者的临床疗效、凝血功能以及血小板聚集的影响.方法 选取2017年1-12月在湖州市第一人民医院心内科治疗的冠心病患者78例为研究对象,患者均进行介入治疗,根据患者在介入治疗时所采取的不同药物治疗将患者分为观察组和对照组各39例.对照组在介入治疗时给予氯吡格雷治疗;观察组给予替格瑞洛治疗.比较两组治疗前后的凝血功能、血小板聚集率.并比较两组临床疗效及满意度.结果 治疗后,观察组凝血酶原时间、活化部分凝血活酶时间、凝血酶时间、纤维蛋白原分别为(12.48 ±1.01)s、(31.91 ±2.53) s、(17.06 ±1.03) s、(4.21 ±1.09) μg／L,均显著优于对照组( t＝18.980、17.092、15.993、11.762,均P＜0.05).观察组总有效率、满意度分别为89.745%(35／39)、97.44%(38／39),均显著高于对照组,差异均有统计学意义(χ2 ＝9.983、8.973,均P＜0.05).结论 对冠心病患者在介入治疗时采用替格瑞洛治疗可以明显缩短患者的凝血酶原时间和活化部分凝血酶原时间,延长凝血酶时间,降低纤维蛋白原和血小板聚集率,而且还可以明显提高临床疗效以及患者满意度.

abstractsObjective To study the effects of ticagrelor on clinical efficacy ,coagulation function and platelet aggregation in patients with coronary heart disease.Methods From January 2017 to December 2017,78 patients in the Department of Cardiology of the First People＇s Hospital of Huzhou were randomly selected in this study.All patients were treated with interventional therapy.According to the different drug used in the interventional therapy ,the patients were divided into the observation group and the control group ,with 39 cases in each group.The patients in the control group were given clopidogrel during interventional therapy ,and the patients in the observation group were given ticagrelor during interventional therapy.The coagulation function and platelet aggregation rate of the patients before and after treatment were observed ,and the clinical efficacy and satisfaction rate of the patients were observed.Results After treatment,the prothrombin time,activated partial thromboplastin time ,thrombin time and fibrinogen level were (12.48 ±1.01) s, (31.91 ±2.53) s, (17.06 ±1.03 ) s and ( 4.21 ±1.09 ) μg／L, respectively, which were significantly better than those in the control group ( t＝18.980,17.092,15.993,11.762,all P＜0.05).The total effective rate and satisfaction rate of the observation group were 89.745% and 97.44%,respectively,which were significantly higher than those of the control group ,and the differences were statisticall significant (χ2 ＝9.983,8.973, all P＜0.05).Conclusion The clinical efficacy of ticagrelor in the interventional treatment of coronary heart disease is significant,which can significantly improve the coagulation function.